missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 18575284

VEGFR3/Flt-4 Antibody (MM0003-7G63), Allophycocyanin, Novus Biologicals™

Mouse Monoclonal Antibody

Brand:  Novus Biologicals NB110-60968APC

Product Code. 18575284

This item is currently unavailable or has been discontinued.
View the product page for possible alternatives.
 View alternative products »

This item is not returnable. View return policy

Description

Description

VEGFR3/Flt-4 Monoclonal antibody specifically detects VEGFR3/Flt-4 in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunohistochemistry (Paraffin)
TRUSTED_SUSTAINABILITY
Specifications

Specifications

VEGFR3/Flt-4
Monoclonal
APC
PBS
Mouse
Protein G purified
RUO
Primary
Human
Purified
Western Blot, Immunohistochemistry, Immunohistochemistry (Paraffin)
MM0003-7G63
Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin
EC 2.7.10, EC 2.7.10.1, FLT-4, fms-related tyrosine kinase 4, LMPH1A, PCLFLT41, soluble VEGFR3 variant 1, soluble VEGFR3 variant 2, soluble VEGFR3 variant 3, Tyrosine-protein kinase receptor FLT4, vascular endothelial growth factor receptor 3, VEGFR-3, VEGFR3Fms-like tyrosine kinase 4
Human VEGFR3/Flt-4 (N-terminal)
0.1 mL
Angiogenesis, Cancer, Hypoxia, Protein Kinase
2324
Store at 4C in the dark.
IgG1
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.